Therefore, both atezolizumab monotherapy or atezolizumab plus chemotherapy could be treatment options for patients with advanced NSCLC and high PD-L1 expression, defined as either greater than 50% PD-L1 expression in the tumor cells (TC) or greater than 10% PD-L1 expression in immune cells (IC) under SP142 PD-L1 immunohistochemistry (IHC) assay (PD-L1 TC3/IC3). This evidence concerns the gene CD274 and non-small cell lung carcinoma.